IP
IOVA icon

Intellectus Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Intellectus Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632K Buy
151,846
+15,400
+11% +$58.5K 0.11% 186
2026
Q1 		$479K Buy
136,446
+4,000
+3% +$12.8K 0.1% 202
2025
Q4 		$362K Buy
132,446
+1,384
+1% +$3.2K 0.07% 216
2025
Q3 		$284K Hold
131,062
– – 0.06% 245
2025
Q2 		$225K Buy
131,062
+14,850
+13% +$37K 0.05% 254
2025
Q1 		$387K Buy
116,212
+1,300
+1% +$6.7K 0.1% 208
2024
Q4 		$850K Buy
114,912
+1,583
+1% +$14.7K 0.19% 147
2024
Q3 		$1.06M Sell
113,329
-600
-0.5% -$5.68K 0.27% 108
2024
Q2 		$914K Sell
113,929
-4,000
-3% -$42.9K 0.25% 111
2024
Q1 		$1.75M Buy
117,929
+1,250
+1% +$14.5K 0.46% 62
2023
Q4 		$949K Sell
116,679
-3,600
-3% -$18.8K 0.27% 103
2023
Q3 		$547K Buy
120,279
+250
+0.2% +$1.63K 0.17% 163
2023
Q2 		$845K Buy
120,029
+11,150
+10% +$79.8K 0.25% 120
2023
Q1 		$665K Buy
108,879
+21,229
+24% +$146K 0.21% 137
2022
Q4 		$560K Buy
87,650
+41,673
+91% +$325K 0.2% 155
2022
Q3 		$440K Hold
45,977
– – 0.16% 168
2022
Q2 		$508K Buy
45,977
+8,377
+22% +$110K 0.17% 162
2022
Q1 		$626K Sell
37,600
-2,500
-6% -$38.7K 0.19% 143
2021
Q4 		$766K Sell
40,100
-18,700
-32% -$412K 0.2% 139
2021
Q3 		$1.45M Buy
58,800
+750
+1% +$17.7K 0.35% 76
2021
Q2 		$1.51M Buy
58,050
+15,500
+36% +$403K 0.34% 75
2021
Q1 		$1.35M Buy
42,550
+950
+2% +$39.4K 0.37% 73
2020
Q4 		$1.93M Buy
41,600
+6,850
+20% +$272K 0.58% 45
2020
Q3 		$1.14M Buy
34,750
+5,015
+17% +$154K 0.43% 67
2020
Q2 		$816K Buy
29,735
+17,900
+151% +$588K 0.32% 95
2020
Q1 		$354K Buy
11,835
+3,100
+35% +$82.2K 0.17% 147
2019
Q4 		$242K Buy
+8,735
New +$199K 0.1% 181

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Intellectus Partners's IOVA Position: Q2 2026 in Review

Intellectus Partners increased its Iovance Biotherapeutics (IOVA) stake by 11% in Q2 2026, buying an estimated $58.5K and bringing the position to 151,846 shares worth $632K. The position accounts for 0.11% of the portfolio, ranked #186.

Intellectus Partners first reported a position in IOVA in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.93M in Q4 2020. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Intellectus Partners held 151,846 shares of Iovance Biotherapeutics worth $632K as of Q2 2026.
  • Intellectus Partners bought 15,400 Iovance Biotherapeutics shares in Q2 2026, an estimated $58.5K.
  • Iovance Biotherapeutics made up 0.11% of Intellectus Partners's portfolio in Q2 2026, its #186 holding.
  • Intellectus Partners first reported a position in Iovance Biotherapeutics in Q4 2019 and has held it in 27 quarters since.
  • Intellectus Partners's Iovance Biotherapeutics position peaked at $1.93M in Q4 2020.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.